Tag: Side Effects

Study Supports More Inclusive Clinical Trials With Broader Eligibility Criteria

—No difference in adverse events, clinical benefit, OS for patients with or without waivers

June 27, 2024 9:00 am

by Charles Bankhead

Patients who received protocol waivers in a clinical trial of targeted anticancer therapy had outcomes similar to those who met all enrollment criteria, a large retrospective review showed.

Patients who received waivers had a clinical benefit rate … Read more

Platinum-resistant ovarian cancer: mirvetuximab soravtansine benefits are maintained in patients who require dose modifications

June 20, 2024 9:00 am

As presented at the ESMO Gynaecological Cancers Congress 2024 (Florence, 20–22 June), a post-hoc analysis of the phase III MIRASOL (GOG 3045/ENGOT-ov55) trial in patients with high folate receptor alpha (FRalpha), platinum-resistant ovarian cancer revealed that even those who required … Read more

Achieving High-Quality Care for Patients With Ovarian Cancer

June 10, 2024 9:00 am

Clearity’s Perspective: This article highlights that some people with ovarian cancer who live in certain geographic locations, like rural areas, may get treated at centers with less experience treating ovarian cancer and/or fewer resources to support whole-person needs. Clearity offers … Read more

Study reveals no survival benefit from systemic therapy in very advanced solid tumors

May 17, 2024 9:00 am

Clearity’s Perspective: Clearity knows that making decisions about continuing treatment when facing advanced ovarian cancer is complicated. Given the difficulty of these decisions, this article suggests having goals-of-care conversations with your medical providers when deciding whether or not to continue … Read more

New Approach May Help People with Cancer Better Manage Depression, Pain, and Fatigue

May 14, 2024 9:00 am

Clearity offers emotional support to individuals with ovarian cancer through our Steps Through OC program. If you would like personal one-to-one assistance with the stress and challenges associated with an ovarian cancer diagnosis, our team of OC Counselors may be … Read more

Yoga shows ‘most improvement’ in restoring brain health in long-term cancer survivors, Northeastern researcher says

May 10, 2024 9:00 am

by Cynthia McCormick Hibbert

For too many cancer survivors, life after treatment is fraught with a decline in cognitive function known as “chemo brain.”

A newly published study by a Northeastern professor says that yoga might hold the key to … Read more

Enhertu Gets Tumor-Agnostic FDA Approval for HER2-Positive Cancers

— About half of patients responded, duration of response as long as 19 months in three trials

April 5, 2024 9:00 am

By Charles Bankhead

The FDA granted tumor-agnostic accelerated approval to trastuzumab deruxtecan (Enhertu) for previously treated unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid cancers.

The action represents the first tumor-agnostic approval for an antibody-drug conjugate targeting HER2-positive tumors. According … Read more

Patients and Doctors Push Back Against the Harsh Side Effects of Cancer Drugs

— “If the patients are not taking the drug, then it’s not going to work”

February 6, 2024 10:30 am

By Associated Press.

For cancer patients, the harsh side effects of powerful drugs have long been the trade-off for living longer. Now, patients and doctors are questioning whether all that suffering is necessary.

They’ve ignited a movement to radically change … Read more

Ovarian Cancer: Best Practices for Managing PARP Inhibitor Side Effects

October 4, 2023 9:00 am

Oncologists treating ovarian cancer need to be proactive to prevent or reduce the likelihood of adverse effects associated with poly (ADP-ribose) polymerase (PARP) inhibitors, noted authors of a review in the ASCO Educational Book.

William Tew, MD, of Memorial Sloan … Read more

REZOLVE (ANZGOG-1101): A Phase 2 Trial of Intraperitoneal Bevacizumab to Treat Symptomatic Ascites in Patients With Chemotherapy-Resistant, Epithelial Ovarian Cancer

February 25, 2021 5:00 pm

For cancer patients, including those with recurrent ovarian cancer, an important cause of morbidity is malignant ascites. Researchers here evaluated the activity of intraperitoneal injections of low-dose bevacizumab in delaying re-accumulation of malignant ascites in women with chemotherapy-resistant epithelial ovarian … Read more

PARP Inhibitors Linked With Blood Cancer Risk

December 28, 2020 11:00 am

Incidence of MDS/AML under 1%, but further investigation warranted as indications broaden

By Leah Lawrence

Although rare, poly-ADP ribose polymerase (PARP) inhibitors were associated with an increased risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), and occurred even … Read more

Study Finds Women with Gynecologic Cancers Have Significant Fatigue After Surgery

July 22, 2020 4:00 pm

These results suggest the need for future studies to examine scalable interventions to improve fatigue in women with gynecologic cancers.

By Hannah Slater

A 1-year longitudinal study published in Cancer suggested that almost half of women with gynecologic cancers had

… Read more

BRCA Mutation, Preventive Surgery, and Osteoporosis

August 8, 2019 4:00 pm

By Kristen Monaco

Researchers advocate for increased hormone therapy for high-risk women.

Bone health suffered in women with a BRCA mutation who underwent preventive oophorectomy, Canadian researchers reported.

Premenopausal women with the BRCA1 or BRCA2 mutation experienced a significant decline … Read more

Choosing Sides: Treatment Decisions for Recurrent Ovarian Cancer Must Consider Side Effects

May 30, 2019 6:00 pm

Patients with ovarian cancer who experience disease recurrences can have potentially helpful options from a large array of drugs, each of which can bring on side effects.

Luckily, doctors have a variety of ways to relieve or prevent these discomforts.

… Read more

Managing Chemotherapy Side Effects for Ovarian Cancer

May 1, 2019 5:15 pm

By Dr. Leslie Boyd

Ovarian cancer produces the type of tumor that oncologists like to call “chemo-sensitive”—which is pretty good news for anyone diagnosed. Ovarian cancer cells have been shown to respond well to a combination of chemo drugs, which … Read more

Individualized Dosing Regimen Reduces Side Effects in Ovarian Cancer Maintenance Therapy

March 18, 2019 7:00 pm

By Kristie L. Kahl

Side effects decreased among patients with high-risk ovarian cancer who received an individualized starting dose of Zejula (niraparib), based upon baseline bodyweight and platelet counts, compared with a fixed starting dose, according to a recent analysis

… Read more

PARP Inhibitor Benefit Gets a TWiST in Recurrent Ovarian Cancer

March 17, 2019 6:00 pm

By Ian Ingram

In delaying disease progression in recurrent ovarian cancer, maintenance therapy with the PARP inhibitor niraparib (Zejula) also increased patients’ time without symptoms or toxicity (TWiST), an analysis of the phase III NOVA trial found.

Compared with placebo, … Read more

Ovarian Cancer Survivors Carry Burden of Severe Long-Term Fatigue

March 14, 2019 5:00 pm

By Will Pass

Women who have survived epithelial ovarian cancer (EOC) more often report severe long-term fatigue than healthy women, according to a case-control study involving more than 600 individuals.

Ovarian cancer survivors had a higher rate of sleep disturbance, … Read more

Real-World Experience Differs from Trial Results for Niraparib in Recurrent Ovarian Cancer

October 25, 2018 1:11 am

By 

Real-world experience of adverse events with the oral PARP inhibitor niraparib in patients with platinum-sensitive recurrent ovarian cancer at a 200 mg daily dose differed from those most commonly seen in the phase 3 clinical trial at … Read more

Quality of Life Maintained With Niraparib for Ovarian Cancer

August 1, 2018 9:19 pm

by Madeline Marr

The use of niraparib in women receiving treatment for platinum-sensitive recurrent ovarian cancer did not adversely affect quality of life (QoL), according to a study published in The Lancet Oncology.

An international team of researchers led … Read more